Amgen’s Cannibalistic Ways

Amgen’s Cannibalistic Ways If you don’t think that Amgen is excited about its future, check out what the company is piling on its plate. The biotech giant will be earmarking half of next year’s revenue to launch a $5 billion share buyback.


FDA Chief Eyes Path for Copycat Biotech Drugs

FDA Chief Eyes Path for Copycat Biotech Drugs Food and Drug Administration Commissioner Mark McClellan said on Friday it may be justifiable for regulators to approve generic forms of biotech drugs even if they have not been through the same lengthy clinical trials required of the original drugs.


Get email updates

Get new actionable insights and updates from BiotechBlog

Biotechblog